Received Oct 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | H4K3S | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Boostrix first dose administration during pregnancy; received two shots of Boostrix (2 months apart) when she was supposed to receive a Human Papillomavirus shot; Boostrix extra dose administration; This non-serious prospective pregnancy case was reported by a pharmacist via call center representative and described the occurrence of vaccine exposure during pregnancy in a 26-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number H4K3S, expiry date 30-OCT-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis and HPV vaccine VLP rL1 2v (baculovirus) (Human papillomavirus (types 16, 18) vaccine, adsorbed) for prophylaxis. On 05-SEP-2025, the patient received the 2nd dose of Boostrix. In JUL-2025, the patient received the 1st dose of Boostrix. The patient did not receive Human papillomavirus (types 16, 18) vaccine, adsorbed. On 05-SEP-2025, an unknown time after receiving Boostrix, the patient experienced wrong vaccine administered (Verbatim: received two shots of Boostrix (2 months apart) when she was supposed to receive a Human Papillomavirus shot) and extra dose administered (Verbatim: Boostrix extra dose administration). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: Boostrix first dose administration during pregnancy). The outcome of the vaccine exposure during pregnancy, wrong vaccine administered and extra dose administered were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Exposure (Boostrix): Trimester unknown Pregnancy Exposure (Human papillomavirus (types 16, 18) vaccine, adsorbed): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-SEP-2025 The reporter asked for safety data after a patient experienced adverse events (medication error events). The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow- up with the reporter.